Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer.
Laboratory studies indicate that nonsteroidal anti-inflammatory drugs (NSAIDs) may inhibit pancreatic cancer, but epidemiologic data to support this finding are limited. We conducted a prospective study from 1992 through 1999 among 28 283 postmenopausal women who lived in Iowa to examine the association between the self-reported use of aspirin and other NSAIDs and the incidence of pancreatic cancer. Eighty incident cases of pancreatic cancer were identified during 7 years of follow-up. The multivariate-adjusted relative risk of pancreatic cancer associated with any current use of aspirin versus no use was 0.57 (95% confidence interval = 0.36 to 0.90). There was a trend of decreasing risk of pancreatic cancer incidence with increasing frequency of aspirin use per week (P(trend) =.005). Nonaspirin NSAID use was not associated with incident pancreatic cancer. These data indicate that aspirin might be chemopreventive for pancreatic cancer.
Anderson
Kristin E
KE
Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis 55454, USA. andeson_k@epi.umn.edu
Johnson
Trista W
TW
Lazovich
DeAnn
D
Folsom
Aaron R
AR
D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D001241:Aspirin / Q000494:pharmacology*; D005260:Female; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000453:epidemiology / Q000517:prevention & control*; D011446:Prospective Studies
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016588:Anticarcinogenic Agents; D001241:Aspirin